Thermo Fisher gains momentum on strong organic growth and biotech recovery, while Becton Dickinson struggles with regulatory hurdles and higher short interest.
Thermo Fisher posted its fastest organic growth since 2021 and received a UBS upgrade despite rotation-driven selling.
Becton Dickinson faces FDA regulatory issues, recalls, and higher short interest, which overshadow its lower valuation and better margins.
Medtronic is mentioned as a stock that could be sold to fund AI rotation, but no specific fundamental update is provided.
Danaher is cited as a potential sale to fund AI trades, with no company-specific news discussed.
Cardinal Health is referenced as an overlooked healthcare name in the rotation discussion, without detailed fundamental analysis.
Thermo Fisher Scientific shares have surged over 8% in September, fueled by the fastest organic growth since 2021 and a bullish upgrade from UBS. While investors previously rotated capital out of healthcare to fund AI bets, improving biotech funding trends are now bolstering the firm's outlook. Conversely, Becton Dickinson faces persistent headwinds from FDA regulatory issues and recalls, keeping sentiment cautious despite its lower valuation.
The stock has benefited from a recovery in biotech funding, which drives demand for the company's research products, alongside strong Q2 organic growth and a positive analyst upgrade from UBS.
Becton Dickinson is currently navigating significant regulatory challenges, including FDA issues with its Alaris system, product recalls, and warning letters, which have contributed to higher short interest.